APA (7th ed.) Citation

Giugliano, R. P., Pedersen, T. R., Park, J., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., . . . Sabatine, M. S. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. The Lancet (British edition), 390(10106), 1962-1971. https://doi.org/10.1016/S0140-6736(17)32290-0

Chicago Style (17th ed.) Citation

Giugliano, Robert P., et al. "Clinical Efficacy and Safety of Achieving Very Low LDL-cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial." The Lancet (British Edition) 390, no. 10106 (2017): 1962-1971. https://doi.org/10.1016/S0140-6736(17)32290-0.

MLA (9th ed.) Citation

Giugliano, Robert P., et al. "Clinical Efficacy and Safety of Achieving Very Low LDL-cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial." The Lancet (British Edition), vol. 390, no. 10106, 2017, pp. 1962-1971, https://doi.org/10.1016/S0140-6736(17)32290-0.